skip to Main Content
Novartis: Branaplam Development Will Continue

Novartis: Branaplam development will continue

Last week Novartis informed the patient community that earlier reports were incorrect and that the development of branaplam as a treatment for SMA will continue.

We are relieved. Branaplam as an oral drug offers considerable promise for people with SMA, even if its development progresses unusually slowly.

Back To Top